Canada markets open in 3 hours 25 minutes

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.5300-0.0200 (-0.44%)
At close: 04:00PM EST
4.7200 +0.19 (+4.19%)
After hours: 06:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close4.5500
Open4.5700
Bid0.0000 x 1000
Ask0.0000 x 1100
Day's Range4.3600 - 4.5700
52 Week Range4.1750 - 9.7900
Volume375,350
Avg. Volume448,035
Market Cap377.293M
Beta (5Y Monthly)0.17
PE Ratio (TTM)13.32
EPS (TTM)0.3400
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
  • GlobeNewswire

    Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

    BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET. A live webcast of the presentation will be avai

  • GlobeNewswire

    Atea Pharmaceuticals Highlights Strategic Priorities for 2023

    Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination Trial of Bemnifosbuvir and Ruzasvir in Patients Infected with Hepatitis C Virus (HCV) with Initial Results Anticipated 4Q23 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:

  • GlobeNewswire

    Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

    BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company’s website at www.atea